Palliative Radiation Therapy for Advanced Gastrointestinal Cancer

Naoya Murakami a Keiichi Nakagawa a Hideomi Yamashita a Hirokazu Nagawa b

Departments of a Radiology and b Surgical Oncology, University of Tokyo Hospital, Tokyo, Japan

Key Words
Palliative radiation therapy • Brachytherapy • Gastrointestinal cancer • Esophageal cancer • Gastric cancer • Colorectal cancer

Abstract
Patients with locally advanced disease can have significant local symptoms. The most common symptoms from local extension are pain, bleeding (hematemesis, melena) and obstruction (dysphagia, vomiting). These can cause a significant impact on a patient’s quality of life. Radiation therapy is used to control these symptoms with modern 3-dimensional conformal techniques or brachytherapy. The aim of this study was therefore to review the outcome of palliative radiation therapy in patients with symptomatic locally advanced or recurrent gastrointestinal cancer.

Introduction

Worldwide, many people suffer from gastrointestinal cancer. About 400,000 patients are diagnosed yearly as having esophageal cancer worldwide, and more than 330,000 die from this disease. Every year about 870,000 patients are diagnosed as having gastric cancer worldwide; more than 640,000 die from this disease. About 940,000 new cases of colorectal cancer are diagnosed yearly and 490,000 patients die from this disease [1]. Although the main modality to eradicate the disease is surgery, many patients cannot receive operation because of the advanced disease stage or medical condition or recurrence of the disease. Given that such patients cannot receive operation for curative intent, they suffer symptoms from advanced disease and need palliative therapy. In this setting, radiotherapy with or without chemotherapy offers such frail patients who are not tough enough to receive operation meaningful symptom relief with acceptable complications. In this article, we review palliative radiotherapy for gastrointestinal cancer.

Esophageal Cancer

Over 50% of the patients with esophageal cancer have inoperable disease at presentation due to advanced disease, metastasis or poor general condition [2]. The majority of patients need palliative treatment to relieve symptoms such as dysphagia, pain or bleeding. At present, several treatment modalities are available for palliation of inoperable esophageal cancer. The treatment options most commonly used nowadays include stent placement [3–7], LASER therapy [8, 9], external beam irradiation...
combined with brachytherapy [10, 11] and brachytherapy as a single treatment (fig. 1) [12–19]. A disadvantage of LASER therapy is that this procedure requires repeat treatment sessions to achieve and maintain a good condition [8, 9], but repeat treatment is not feasible for patients in a poor medical condition. A combined treatment of external beam radiation with brachytherapy is often too intensive for patients of poor performance status. Therefore, in many patients with inoperable disease, placement of metal stent or single-dose brachytherapy is used for the palliation of dysphagia. One randomized trial has been published for the palliation of dysphagia from esophageal cancer [20]. In total 209 patients were randomized to single-dose (12 Gy) brachytherapy or stent placement (Ultraflex stent). Dysphagia improved more rapidly after stent placement than after single brachytherapy, but long-term relief of dysphagia and health-related quality of life scores were better after brachytherapy. Complications occurred more frequently after stent placement (total complications: 33 vs. 21%), especially hemorrhage. The treatment groups did not differ for persistent or recurrent dysphagia, about 40% of either modality group of patients required some kind of second therapy. Whether a single treatment of 12-Gy brachytherapy was the optimum dose, or whether a raised or fractionated dose might improve the biological effects of brachytherapy, is debatable. Different doses of brachytherapy were compared previously in 172 patients with advanced esophageal (mainly squamous cell) carcinoma [16]. With respect to dysphagia-free survival and persistent tumor growth, the patients who received 16 Gy in 2 sessions or 18 Gy in 3 sessions did significantly better than those who received 12 Gy in 2 sessions after treatment. Homs et al. [20] concluded in their paper that single-dose brachytherapy is preferable to stent placement as the initial treatment for patients with dysphagia from inoperable esophageal can-
cer. Stent placement may be reserved for patients with severe dysphagia whose life expectancy is short and where rapid symptom relief is needed. The consensus guidelines of the American Brachytherapy Society have distinguished several criteria (based on tumor characteristics) to group patients as good candidates, poor candidates and patients with contraindications for brachytherapy [21]. The contraindications for brachytherapy described by the American Brachytherapy Society include an esophageal fistula and a cervical esophageal location of the tumor and a stenotic tumor that cannot be bypassed.

**Gastric Cancer**

Patients with localized gastric cancer have a higher 5-year survival rate (59%) compared with regional (21.9%) or distant disease (3.1%) [22]. Unfortunately, only 25–40% of the patients have localized disease at diagnosis and will be able to undergo potentially curative surgical resection [23]. The 3 most common symptoms from local extension are pain, bleeding (hematemesis, melena) and obstruction (dysphagia, vomiting). These can cause a significant impact on a patient’s quality of life. Tey et al. [24] retrospectively evaluated the outcome of palliative radiation therapy (RT) alone in patients with symptomatic locally advanced or recurrent gastric cancer managed with modern RT techniques (CT-based radiation). Thirty-three patients with locally advanced/recurrent gastric cancer were treated palliatively with RT alone at the Cancer Institute radiotherapy centers between November 1999 and December 2004. All patients received external beam RT. In the analysis of the response rate, 13 of 24 patients with bleeding (54%), 2 of 8 patients with pain (25%) and 2 of 8 patients with obstruction (25%) responded to radiotherapy. The median duration of response was 140, 102 and 105 days for patients with bleeding, pain and obstruction, and the mean percent net relief (the ratio between the duration of symptom relief and survival multiplied by 100) [25] was 65.3, 66.3 and 71%, respectively. Although efficacy is mainly limited to patients who present with bleeding, external beam RT may still be considered for patients presenting with obstruction or pain because responses are possible. A response rate of at least 25% is reasonable, given that most patients may have failed chemotherapy and only received RT for palliative therapy. If patients do respond to radiation, the responses are often durable no matter what the symptom is.

If the general condition of patients with inoperable advanced gastric cancer is good enough to undergo chemoradiotherapy, not only symptom relief but also survival benefit can be expected by combined-modality therapy (5-year survivals of 5–15%) [26]. Table 1 shows treatment results of unresectable or residual gastric cancer treated by radiotherapy with or without chemotherapy [27–31].

### Table 1. Treatment results: unresectable or residual gastric cancer

<table>
<thead>
<tr>
<th>Reference</th>
<th>n</th>
<th>Treatment</th>
<th>Radiation therapy</th>
<th>Chemotherapy</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Randomized</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mayo Clinic [28]</td>
<td>48</td>
<td>EBRT ± CT</td>
<td>35–37.5 Gy in 4–5 weeks</td>
<td>5-FU 1st week of EBRT</td>
<td>median survival 13 vs. 6 months and 5-year overall survival 12 vs. 0%, favoring EBRT + 5-FU</td>
</tr>
<tr>
<td>GITSG [29]</td>
<td>90</td>
<td>CT ± EBRT</td>
<td>50 Gy split course in 8 weeks</td>
<td>5-FU during EBRT, maintenance 5-FU/MeCCNU 5-FU</td>
<td>4-year survival 18 vs. 7%, favoring CT + EBRT</td>
</tr>
<tr>
<td>EORTIC [30]</td>
<td>90</td>
<td>EBRT ± CT</td>
<td>55.5 Gy in 6 weeks</td>
<td>5-FU</td>
<td>14% long-term survival (3 patients) with EBRT + 5-FU</td>
</tr>
<tr>
<td><strong>Retrospective</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGH [31]</td>
<td>32</td>
<td>EBRT ± CT</td>
<td>45–55 Gy in 5 weeks</td>
<td>5-FU during EBRT, maintenance 5-FU/MeCCNU</td>
<td>EBRT + CT; unresectable disease 14 months median survival; unresectable and residual disease 10% 4-year survival</td>
</tr>
</tbody>
</table>

EBRT = External beam radiation therapy; CT = chemotherapy; 5-FU = 5-fluorouracil; MeCCNU = semustine; GITSG = Gastrointestinal Study Group; EORTC = European Organization for Research and Treatment of Cancer; MGH = Massachusetts General Hospital.
phase III trials for unresectable or residual gastric cancer show an advantage for combined-modality treatment over single-modality treatment. Radiation doses range from 35 to 55.5 Gy in 1.5–2.0 fractions. Most chemotherapies mainly consist of 5-fluorouracil. These populations of patients achieve a 5-year overall survival of about 15% by combined treatment of radiation and chemotherapy.

**Colorectal Cancer**

The mainstay of treatment for rectal and low sigmoid colon cancer is surgical resection with or without adjuvant chemoradiation. There are, however, patients for whom this is inappropriate either because of their general condition or because of recurrent tumor or locally...
advanced tumor in face of widespread metastatic disease. In this setting, radiotherapy or chemotherapy may have an important role for local tumor control and symptom relief. External beam techniques to treat this area may be limited in achieving a high dose by the tolerance of large and small bowel, bladder and skin. Brachytherapy carries the advantage of being able to deliver a localized high dose of radiation with rapid fall-off of dose and sparing of adjacent normal tissues. Access to the rectal lumen is simple and therefore provides an ideal opportunity for delivering high-dose local radiation by brachytherapy.

Hoskin et al. [32] reported 10 years of experience of intraluminal brachytherapy for advanced inoperable rectal carcinoma, both boost treatment alongside external beam chemoradiation and sole treatment for small localized tumors at Mount Vernon Hospital. Between October 1992 and December 2001, a total of 50 patients were treated with brachytherapy. Treatment is delivered in the high-

Table 2. Presenting symptoms

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bleeding</td>
<td>28</td>
</tr>
<tr>
<td>Mucous discharge</td>
<td>14</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>10</td>
</tr>
<tr>
<td>Pain</td>
<td>8</td>
</tr>
<tr>
<td>Tenesmus</td>
<td>5</td>
</tr>
<tr>
<td>Constipation</td>
<td>4</td>
</tr>
<tr>
<td>Fecal incontinence</td>
<td>2</td>
</tr>
<tr>
<td>Obstruction</td>
<td>1</td>
</tr>
</tbody>
</table>

No patient was symptom free; 20 had a single symptom, of whom 10 had bleeding; 17 had 2 symptoms and 6 had 3 symptoms, hence the total number of symptoms is 72.

Table 3. Response rate and duration

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Complete response</th>
<th>Partial response</th>
<th>No change</th>
<th>Lost to follow-up</th>
<th>Response duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucous</td>
<td>4 (28)</td>
<td>5 (36)</td>
<td>4</td>
<td>1</td>
<td>Median, months</td>
</tr>
<tr>
<td>(n=14)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>Bleeding</td>
<td>16 (57)</td>
<td>2 (7)</td>
<td>0</td>
<td>10</td>
<td>Range, months</td>
</tr>
<tr>
<td>(n=28)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1-28</td>
</tr>
<tr>
<td>Pain</td>
<td>4 (50)</td>
<td>3 (37)</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>(n=8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>6 (60)</td>
<td>4 (40)</td>
<td></td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>(n=10)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figures in parentheses are percentages.
high-dose-rate intraluminal brachytherapy is a simple outpatient procedure with minimal acute toxicity for the management of anorectal carcinoma. It has a particular role in the treatment of the frail elderly patient unable to tolerate more intensive treatment offering effective and durable palliation of advanced disease.

If the locally advanced or recurrent tumor is large enough to be covered with a single intraluminal applicator or the tumor obstructs the lumen to insert the applicator, interstitial brachytherapy is applied. Kolotas et al. [33] treated 38 patients with recurrent rectal cancer after surgery. The mean tumor volume was 336.5 ml and they used either transsacral implantation (in case of sacrum invasion, fig. 4) with 10–15-Gy single dose or transperineal implantation (fig. 5) with 5-Gy fractions twice daily for 30–40 Gy. Although the tumor response was not so good (6/38 partial remission, 28/38 stable disease and 4/38 local progression), they achieved a meaningful symptom relief [pain: 34/38 patients (89.5%), reduction of analgesics: 25/38 (65.7%)] and durable effect (percent net pain relief = 66%). There was no mortality associated with the treatment, and morbidity was limited: 1 patient with fistula and 1 with ulceration of the perineal area. The approaches described above for locally unresectable rectal cancer recurrences can be performed safely and can provide effective palliation. high-dose-rate brachytherapy technique delivers high-dose fractions to the tumor in a short time while keeping the dose to the surrounding organs at a low level. This aspect is especially important for preirradiated patients.

Disclosure Statement

The authors declare that no financial or other conflict of interest exists in relation to the content of the article.

References

Palliative Radiation Therapy for Advanced Gastrointestinal Cancer


